机构:[1]Department of Endocrinology, Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, China[2]School of Pharmacy, University of Queensland, Pharmacy Australia Centre of Excellence, Woolloongabba, QLD, Australia[3]Guangdong Province Key Laboratory of Pharmacodynamic Constituents of Traditional Chinese Medicine and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, China[4]Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Pathology of School of Basic Medical Sciences, Fudan University, Shanghai, China[5]Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, Australia[6]Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA[7]Laboratory of Metabolics and Cardiovascular Diseases, Institute of Endocrine and Metabolic Diseases, University of Science and Technology of China, Hefei, China[8]Biomedical Sciences and Health Laboratory of Anhui Province, University of Science and Technology of China, Hefei, China
This study was supported by grants from National Key R&D Program of China (grant 2021YFC2500500), the National Natural
Science Foundation of China (82070464, 81941022, 81530025, 81870324), and the Strategic Priority Research Program of
Chinese Academy of Sciences (XDB38010100). This work was also supported by the Program for Innovative Research Team
of the First Affiliated Hospital of USTC (CXGG02), the Anhui Provincial Key Research and Development Program
(202104j07020051), Anhui Province Science Fund for Distinguished Young Scholors (Grant No. 2208085J08), the Local Innovative
and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131), and National Institutes
of Health (NIH) grants HL140958 and HL134910 (to B.C.B.).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|1 区医学
小类|1 区药学
最新[2025]版:
大类|1 区医学
小类|1 区药学
第一作者:
第一作者机构:[1]Department of Endocrinology, Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, China
通讯作者:
通讯机构:[1]Department of Endocrinology, Institute of Endocrine and Metabolic Diseases, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Clinical Research Hospital of Chinese Academy of Sciences (Hefei), University of Science and Technology of China, Hefei, China[7]Laboratory of Metabolics and Cardiovascular Diseases, Institute of Endocrine and Metabolic Diseases, University of Science and Technology of China, Hefei, China[8]Biomedical Sciences and Health Laboratory of Anhui Province, University of Science and Technology of China, Hefei, China
推荐引用方式(GB/T 7714):
Ilyas Iqra,Little Peter J,Liu Zhiping,et al.Mouse models of atherosclerosis in translational research[J].Trends in pharmacological sciences.2022,doi:10.1016/j.tips.2022.06.009.
APA:
Ilyas Iqra,Little Peter J,Liu Zhiping,Xu Yanyong,Kamato Danielle...&Xu Suowen.(2022).Mouse models of atherosclerosis in translational research.Trends in pharmacological sciences,,
MLA:
Ilyas Iqra,et al."Mouse models of atherosclerosis in translational research".Trends in pharmacological sciences .(2022)